1 citations
,
September 2020 in “Cochrane library (CD-ROM)” The analysis aims to identify the most effective and safest treatments for alopecia areata.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
40 citations
,
September 2014 in “Journal of cosmetic and laser therapy” Transepidermal drug delivery effectively treated areata alopecia with minimal side effects.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
Belimumab effectively controls SLE disease activity and reduces steroid use.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
7 citations
,
December 2022 in “Skin Appendage Disorders” Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
12 citations
,
July 2012 in “Journal of cutaneous medicine and surgery” Adalimumab was safe but mostly ineffective for severe alopecia areata.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
67 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.
60 citations
,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
59 citations
,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
35 citations
,
May 2012 in “Expert Opinion on Pharmacotherapy” The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.
30 citations
,
July 2019 in “PloS one” Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
26 citations
,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
24 citations
,
June 2018 in “Expert Review of Pharmacoeconomics & Outcomes Research” Microneedle technology is beneficial for drug delivery and could make vaccinations cheaper and more accessible.